LOS ANGELES--(BUSINESS WIRE)--July 24, 2006--CytRx Corporation (Nasdaq:CYTR - News), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that the final patients have completed dosing and follow-up with arimoclomol in the Company’s Phase IIa clinical trial for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). Phase IIa patients were evaluated while receiving either placebo (a capsule without drug) or one of three dose levels of CytRx’s lead product candidate arimoclomol three times daily for 12 weeks and during a 4-week follow-up period without drug.
